The VABREMA MITOPLICATOR is able to expose biological cells in their normal culture medium to an electromagnetic field of nanosecond duration with field strength of more than 10.000V/cm.

1 These fields last only a few nanoseconds, which means:
a) that their energy density is extremely low. Thus keeping the cells viable.
b) that the fields are faster than the response time of a cell’s plasma membrane. Thus allowing voltage differences to build up on the cells interior structures.

2 These voltage differences will enable a temporary increase of the permeability of the cells interior structures, leading to the formation of short-lived nanopores in the intracellular structures.

3 The formation of nanopores supports intracellular release of calcium.

This in turn triggers a wave of mitosis.


Increase proliferation rate without interfering with the process.
What if you could trigger your cells in culture to GROW FASTER? Induce a wave of MITOSIS, without need for clone selection, medium optimalisation or reactor changes. Interested? Try Mitoplication: Promoting cell proliferation by means of nanosecond pulsed electrical fields.


The MITOPLICATOR Technology can improve the performance of your cell culture. Estimates show that production costs can be lowered 30 to 60%. Furthermore the technology is scalable and can be fully integrated in existing culture systems, which means:
- increase cell proliferation
- increase titer existing process
- reduce time span clone selection
- reduce backup reactor cost
- reduce seed time span


Promising solutions in the lab often appear less promising once they have to be produced in large quantities.
Scalable, efficient and cost-effective cell culture is a prerequisite for many applications in modern medicine. Whether we talk about high-value therapeutic protein production or cell therapies, it is a prerequisite that the biological cells used can be cultured in a way that is scalable, efficient and cost-effective. That is, however, far from trivial. Low amplification factors, and time and labor intensive culture methods make the production costs of a therapeutic protein very high in comparison with the production of a conventional small-molecule drug. And it’s even worse for many cell therapies were the limited supplies of raw materials can be a real show stopper. Only too often promising solutions in the lab appear less promising once they have to be produced in larger quantities.

Today if one is faced with a poorly performing cell culture, the only option is to spend months on screening of large numbers of clones, enhancing media formulations and optimizing reactor designs.